Market closed
ESSA Pharma/$EPIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ESSA Pharma
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
Ticker
$EPIX
Sector
Trading on
Industry
Biotechnology
Headquarters
Vancouver, Canada
Employees
35
Website
ESSA Pharma Metrics
BasicAdvanced
$70M
-
-$0.70
1.61
-
Price and volume
Market cap
$70M
Beta
1.61
52-week high
$8.60
52-week low
$1.40
Average daily volume
94K
Financial strength
Current ratio
33.115
Quick ratio
32.736
Long term debt to equity
0.152
Total debt to equity
0.257
Management effectiveness
Return on assets (TTM)
-17.09%
Return on equity (TTM)
-23.98%
Valuation
Price to book
0.59
Price to tangible book (TTM)
0.59
Price to free cash flow (TTM)
-3.128
Growth
Earnings per share change (TTM)
19.31%
3-year earnings per share growth (CAGR)
-9.83%
What the Analysts think about ESSA Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ESSA Pharma stock.
ESSA Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ESSA Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ESSA Pharma News
AllArticlesVideos
Shareholders of ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
Accesswire·1 week ago
EPIX Deadline Today: Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Business Wire·1 week ago
ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX
Accesswire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ESSA Pharma stock?
ESSA Pharma (EPIX) has a market cap of $70M as of April 04, 2025.
What is the P/E ratio for ESSA Pharma stock?
The price to earnings (P/E) ratio for ESSA Pharma (EPIX) stock is 0 as of April 04, 2025.
Does ESSA Pharma stock pay dividends?
No, ESSA Pharma (EPIX) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next ESSA Pharma dividend payment date?
ESSA Pharma (EPIX) stock does not pay dividends to its shareholders.
What is the beta indicator for ESSA Pharma?
ESSA Pharma (EPIX) has a beta rating of 1.61. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.